Top

Published in:

Open Access 01-12-2021 | Fertility | Review

A review on the relationship between anti-mullerian hormone and fertility in treating young breast cancer patients

Authors: Yixuan Song, Hong Liu

Published in: BMC Women's Health | Issue 1/2021

Abstract

Despite the fact that the long-term survival rate of breast cancer patients had been significantly improved owing to the systemic breast cancer therapies, there are still some side effects such as amenorrhea and fertility retention to be resolved, leaving it an important thing to understand the possible side effects on fertility and fertility preservation strategies while undergoing breast cancer treatment, due to the fact that most young patients hope to become pregnant and have children after breast cancer treatment. With anti-müllerian hormone (AMH) being the most sensitive marker for predicting ovarian function in young premenopausal women with breast cancer, this review is aimed to provide the additional guidance for clinical application of AMH by exploring the impacts of AMH on the fertility of young breast cancer patients, the relationship between AMH and metabolism, and the relationship between BRAC gene mutation and fertility protection strategies.

Li J, Zhang BN, Fan JH, Pang Y, Zhang P, Wang SL, et al. A nation-wide multicenter 10-year (1999–2008) retrospective clinical epidemiological study of female breast cancer in China. BMC Cancer. 2011;11:364. PubMedPubMedCentralCrossRef

Kasum M, Beketić-Orešković L, Peddi PF, Orešković S, Johnson RH. Fertility after breast cancer treatment. Eur J Obstet Gynecol Reprod Biol. 2014;173:13–8.PubMedCrossRef

Ruddy KJ, Gelber SI, Tamimi RM, Ginsburg ES, Schapira L, Come SE, et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol. 2014;32(11):1151–6.PubMedPubMedCentralCrossRef

Simon B, Lee SJ, Partridge AH, Runowicz CD. Preserving fertility after cancer. CA Cancer J Clin. 2005;55(4):211–28; quiz 63–4.

Bedoschi G, Navarro PA, Oktay K. Chemotherapy-induced damage to ovary: mechanisms and clinical impact. Fut Oncol. 2016;12(20):2333–44.CrossRef

Visser JA, de Jong FH, Laven JS, Themmen AP. Anti-Mullerian hormone: a new marker for ovarian function. Reproduction. 2006;131(1):1–9.PubMedCrossRef

Ruddy KJ, O’Neill A, Miller KD, Schneider BP, Baker E, Sparano JA, et al. Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103. Breast Cancer Res Treat. 2014;144(3):591–7.PubMedPubMedCentralCrossRef

Silva C, Ribeiro Rama AC, Reis Soares S, Moura-Ramos M, Almeida-Santos T. Adverse reproductive health outcomes in a cohort of young women with breast cancer exposed to systemic treatments. J Ovar Res. 2019;12(1):102.CrossRef

Kano M, Sosulski AE, Zhang L, Saatcioglu HD, Wang D, Nagykery N, et al. AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy. Proc Natl Acad Sci USA. 2017;114(9):E1688–97.PubMedPubMedCentralCrossRef

10.

Kalich-Philosoph L, Roness H, Carmely A, Fishel-Bartal M, Ligumsky H, Paglin S, et al. Cyclophosphamide triggers follicle activation and “burnout”; AS101 prevents follicle loss and preserves fertility. Sci Transl Med. 2013;5(185):18562.CrossRef

11.

Sonigo C, Beau I, Grynberg M, Binart N. AMH prevents primordial ovarian follicle loss and fertility alteration in cyclophosphamide-treated mice. FASEB J. 2019;33(1):1278–87.PubMedCrossRef

12.

Reddy P, Zheng W, Liu K. Mechanisms maintaining the dormancy and survival of mammalian primordial follicles. Trends Endocrinol Metab. 2010;21(2):96–103.PubMedCrossRef

13.

Hayes E, Kushnir V, Ma X, Biswas A, Prizant H, Gleicher N, et al. Intra-cellular mechanism of Anti-Müllerian hormone (AMH) in regulation of follicular development. Mol Cell Endocrinol. 2016;433:56–65.PubMedCrossRef

14.

Adhikari D, Liu K. Molecular mechanisms underlying the activation of mammalian primordial follicles. Endocr Rev. 2009;30(5):438–64.PubMedCrossRef

15.

Liu K, Rajareddy S, Liu L, Jagarlamudi K, Boman K, Selstam G, et al. Control of mammalian oocyte growth and early follicular development by the oocyte PI3 kinase pathway: new roles for an old timer. Dev Biol. 2006;299(1):1–11.PubMedCrossRef

16.

Nilsson E, Rogers N, Skinner MK. Actions of anti-Mullerian hormone on the ovarian transcriptome to inhibit primordial to primary follicle transition. Reproduction. 2007;134(2):209–21.PubMedPubMedCentralCrossRef

17.

Hu R, Wang F-m, Yu L, Luo Y, Wu X, Li J, et al. Antimüllerian hormone regulates stem cell factor expression in human granulosa cells. Fertil Steril. 2014;102(6):1742–50.e1.

18.

Fu Y-X, Wang F-M, Ou-Yang X-E, Yang H-M, Hu T, Wang Y-F, et al. Anti-Müllerian hormone regulates stem cell factor via cAMP/PKA signaling pathway in human granulosa cells by inhibiting the phosphorylation of CREB. Reprod Sci. 2020;27(1):325–33.PubMedCrossRef

19.

Amir E, Freedman O, Allen L, Colgan T, Clemons M. Defining ovarian failure in amenorrheic young breast cancer patients. Breast. 2010;19(6):545–8.PubMedCrossRef

20.

Maltaris T, Boehm D, Dittrich R, Seufert R, Koelbl H. Reproduction beyond cancer: a message of hope for young women. Gynecol Oncol. 2006;103(3):1109–21.PubMedCrossRef

21.

Loubersac S, Dezellus A, Lefebvre T, Reignier A, Barriere P, Masson D, et al. Evolution of serum anti-Müllerian Hormone (AMH) level in young women treated with chemotherapy for breast cancer according to basal AMH level. Eur J Obstet Gynecol Reprod Biol. 2020;254:132–7.PubMedCrossRef

22.

Morgan S, Anderson RA, Gourley C, Wallace WH, Spears N. How do chemotherapeutic agents damage the ovary? Hum Reprod Update. 2012;18(5):525–35.PubMedCrossRef

23.

D’Avila AM, Capp E, Corleta HVE. Antral follicles count and anti-Mullerian hormone levels after gonadotoxic chemotherapy in patients with breast cancer: cohort study. Revista brasileira de ginecologia e obstetricia. 2017;39(4):162–8.PubMedCrossRef

24.

Kim HA, Choi J, Park CS, Seong MK, Hong SE, Kim JS, et al. Post-chemotherapy serum anti-Mullerian hormone level predicts ovarian function recovery. Endocr Connect. 2018;7(8):949–56.PubMedPubMedCentralCrossRef

25.

Trapp E, Steidl J, Rack B, Kupka MS, Andergassen U, Juckstock J, et al. Anti-Mullerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy—a translational research project of the SUCCESS A study. Breast. 2017;35:130–5.PubMedCrossRef

26.

Anderson RA, Cameron DA. Pretreatment serum anti-mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab. 2011;96(5):1336–43.PubMedCrossRef

27.

D'Avila ÂM, Biolchi V, Capp E, Corleta HvE. Age, anti-müllerian hormone, antral follicles count to predict amenorrhea or oligomenorrhea after chemotherapy with cyclophosphamide. J Ovar Res. 2015;8:82.

28.

Dillon KE, Sammel MD, Prewitt M, Ginsberg JP, Walker D, Mersereau JE, et al. Pretreatment antimullerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil Steril. 2013;99(2):477–83.PubMedCrossRef

29.

Xue C, Wei W, Sun P, Zheng W, Diao X, Xu F, et al. Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer. Breast Cancer Res Treat. 2019;173(3):619–28.PubMedCrossRef

30.

Hickey M, Peate M, Saunders CM, Friedlander M. Breast cancer in young women and its impact on reproductive function. Hum Reprod Update. 2009;15(3):323–39.PubMedPubMedCentralCrossRef

31.

Jung M, Shin HJ, Rha SY, Jeung HC, Hong S, Moon YW, et al. The clinical outcome of chemotherapy-induced amenorrhea in premenopausal young patients with breast cancer with long-term follow-up. Ann Surg Oncol. 2010;17(12):3259–68.PubMedCrossRef

32.

Fornier MN, Modi S, Panageas KS, Norton L, Hudis C. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer. 2005;104(8):1575–9.PubMedCrossRef

33.

Shandley LM, Spencer JB, Fothergill A, Mertens AC, Manatunga A, Paplomata E, et al. Impact of tamoxifen therapy on fertility in breast cancer survivors. Fertil Steril. 2017;107(1):243-52.e5.PubMedCrossRef

34.

Decanter C, Cloquet M, Dassonneville A, D’Orazio E, Mailliez A, Pigny P. Different patterns of ovarian recovery after cancer treatment suggest various individual ovarian susceptibilities to chemotherapy. Reprod Biomed Online. 2018;36(6):711–8.PubMedCrossRef

35.

Schuurman TN, Witteveen PO, van der Wall E, Passier JLM, Huitema ADR, Amant F, et al. Tamoxifen and pregnancy: an absolute contraindication? Breast Cancer Res Treat. 2019;175(1):17–25.PubMedCrossRef

36.

Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial. J Clin Oncol. 2016;34(10):1034–42.PubMedCrossRef

37.

Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273–83.PubMedPubMedCentralCrossRef

38.

Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17(6):791–800.PubMedCrossRef

39.

Ruddy KJ, Guo H, Barry W, Dang CT, Yardley DA, Moy B, et al. Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). Breast Cancer Res Treat. 2015;151(3):589–96.PubMedPubMedCentralCrossRef

40.

Morarji K, McArdle O, Hui K, Gingras-Hill G, Ahmed S, Greenblatt EM, et al. Ovarian function after chemotherapy in young breast cancer survivors. Curr Oncol. 2017;24(6):e494–502.PubMedPubMedCentralCrossRef

41.

Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108(2):171–82.PubMedCrossRef

42.

Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402–16.PubMedCrossRef

43.

Andrieu N, Goldgar DE, Easton DF, Rookus M, Brohet R, Antoniou AC, et al. Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). J Natl Cancer Inst. 2006;98(8):535–44.PubMedCrossRef

44.

Oktay KH, Bedoschi G, Goldfarb SB, Taylan E, Titus S, Palomaki GE, et al. Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency. Fertil Steril. 2020;113(6):1251-60.e1.PubMedPubMedCentralCrossRef

45.

Oktay K, Kim JY, Barad D, Babayev SN. Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol. 2010;28(2):240–4.PubMedCrossRef

46.

Shapira M, Raanani H, Feldman B, Srebnik N, Dereck-Haim S, Manela D, et al. BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles. Fertil Steril. 2015;104(5):1162–7.PubMedCrossRef

47.

Lambertini M, Goldrat O, Ferreira AR, Dechene J, Azim HA Jr, Desir J, et al. Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients. Ann Oncol. 2018;29(1):237–43.PubMedCrossRef

48.

Turan V, Oktay K. BRCA-related ATM-mediated DNA double-strand break repair and ovarian aging. Hum Reprod Update. 2020;26(1):43–57.PubMedCrossRef

49.

Phillips KA, Collins IM, Milne RL, McLachlan SA, Friedlander M, Hickey M, et al. Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations. Hum Reprod. 2016;31(5):1126–32.PubMedPubMedCentralCrossRef

50.

Titus S, Li F, Stobezki R, Akula K, Unsal E, Jeong K, et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med. 2013;5(172):172ra21.

51.

Winship AL, Willson C, Hansen KR, Hutt KJ, Hickey M. Do BRCA1 and BRCA2 gene mutation carriers have a reduced ovarian reserve? Protocol for a prospective observational study. BMJ Open. 2019;9(11):e033810.PubMedPubMedCentralCrossRef

52.

Derks-Smeets IAP, van Tilborg TC, van Montfoort A, Smits L, Torrance HL, Meijer-Hoogeveen M, et al. BRCA1 mutation carriers have a lower number of mature oocytes after ovarian stimulation for IVF/PGD. J Assist Reprod Genet. 2017;34(11):1475–82.PubMedPubMedCentralCrossRef

53.

Son KA, Lee DY, Choi D. Association of BRCA mutations and anti-Mullerian hormone level in young breast cancer patients. Front Endocrinol. 2019;10:235.CrossRef

54.

Birch Petersen K, Hvidman HW, Forman JL, Pinborg A, Larsen EC, Macklon KT, et al. Ovarian reserve assessment in users of oral contraception seeking fertility advice on their reproductive lifespan. Hum Reprod. 2015;30(10):2364–75.PubMedCrossRef

55.

Chu J, Gallos I, Tobias A, Tan B, Eapen A, Coomarasamy A. Vitamin D and assisted reproductive treatment outcome: a systematic review and meta-analysis. Hum Reprod. 2018;33(1):65–80.PubMedCrossRef

56.

Merhi Z, Doswell A, Krebs K, Cipolla M. Vitamin D alters genes involved in follicular development and steroidogenesis in human cumulus granulosa cells. J Clin Endocrinol Metab. 2014;99(6):E1137–45.PubMedPubMedCentralCrossRef

57.

Dennis NA, Houghton LA, Pankhurst MW, Harper MJ, McLennan IS. Acute supplementation with high dose vitamin D3 increases serum anti-Müllerian hormone in young women. Nutrients. 2017;9(7):719.CrossRefPubMedCentral

58.

Drakopoulos P, van de Vijver A, Schutyser V, Milatovic S, Anckaert E, Schiettecatte J, et al. The effect of serum vitamin D levels on ovarian reserve markers: a prospective cross-sectional study. Hum Reprod. 2017;32(1):208–14.PubMed

59.

Pearce K, Gleeson K, Tremellen K. Serum anti-Mullerian hormone production is not correlated with seasonal fluctuations of vitamin D status in ovulatory or PCOS women. Hum Reprod. 2015;30(9):2171–7.PubMedCrossRef

60.

Shapiro AJ, Darmon SK, Barad DH, Gleicher N, Kushnir VA. Vitamin D levels are not associated with ovarian reserve in a group of infertile women with a high prevalance of diminished ovarian reserve. Fertil Steril. 2018;110(4):761-6.e1.PubMedCrossRef

61.

Zeynep OD. Berna DJJTGGA. Impact of obesity on infertility in women. 2015;16(2):111–7.

62.

Buyuk E, Seifer DB, Illions E, Grazi RV, Lieman H. Elevated body mass index is associated with lower serum anti-mullerian hormone levels in infertile women with diminished ovarian reserve but not with normal ovarian reserve. Fertil Steril. 2011;95(7):2364–8.PubMedCrossRef

63.

Park AS, Lawson MA, Chuan SS, Oberfield SE, Hoeger KM, Witchel SF, et al. Serum anti-mullerian hormone concentrations are elevated in oligomenorrheic girls without evidence of hyperandrogenism. J Clin Endocrinol Metab. 2010;95(4):1786–92.PubMedPubMedCentralCrossRef

64.

Hohos NM, Skaznik-Wikiel ME. High-fat diet and female fertility. Endocrinology. 2017;158(8):2407–19.PubMedPubMedCentralCrossRef

65.

Skaznik-Wikiel ME, Swindle DC, Allshouse AA, Polotsky AJ, McManaman JL. High-fat diet causes subfertility and compromised ovarian function independent of obesity in mice. Biol Reprod. 2016;94(5):108.PubMedPubMedCentralCrossRef

66.

Anderson C, Mark Park Y-M, Stanczyk FZ, Sandler DP, Nichols HB. Dietary factors and serum antimüllerian hormone concentrations in late premenopausal women. Fertil Steril. 2018;110(6):1145–53.PubMedPubMedCentralCrossRef

67.

Su H-CI, Haunschild C, Chung K, Komrokian S, Boles S, Sammel MD, et al. Prechemotherapy antimullerian hormone, age, and body size predict timing of return of ovarian function in young breast cancer patients. Cancer. 2014;120(23):3691–8.

68.

Sonigo C, Beau I, Binart N, Grynberg M. Anti-Müllerian hormone in fertility preservation: clinical and therapeutic applications. Clin Med Insights Reprod Health. 2019;13:1179558119854755.

69.

Pursche T, Bauer J, Hammersen F, Rody A, Waldmann A, Fischer D. Early-onset breast cancer: effect of diagnosis and therapy on fertility concerns, endocrine system, and sexuality of young mothers in Germany. Breast Care. 2019;14(1):23–9.PubMedCrossRef

70.

Lee RJ, Wakefield A, Foy S, Howell SJ, Wardley AM, Armstrong AC. Facilitating reproductive choices: the impact of health services on the experiences of young women with breast cancer. Psychooncology. 2011;20(10):1044–52.PubMedCrossRef

71.

Vuković P, Kasum M, Raguž J, Lonjak N, BilićKnežević S, Orešković I, et al. Fertility preservation in young women with early-stage breast cancer. Acta Clin Croat. 2019;58(1):147–56.PubMedPubMedCentral

72.

Cobo A, García-Velasco JA, Coello A, Domingo J, Pellicer A, Remohí J. Oocyte vitrification as an efficient option for elective fertility preservation. Fertil Steril. 2016;105(3):755-64.e8.PubMedCrossRef

73.

Gremeau A-S, Andreadis N, Fatum M, Craig J, Turner K, McVeigh E, et al. In vitro maturation or in vitro fertilization for women with polycystic ovaries? A case-control study of 194 treatment cycles. Fertil Steril. 2012;98(2):355–60.PubMedCrossRef

74.

Sonigo C, Simon C, Boubaya M, Benoit A, Sifer C, Sermondade N, et al. What threshold values of antral follicle count and serum AMH levels should be considered for oocyte cryopreservation after in vitro maturation? Hum Reprod. 2016;31(7):1493–500.PubMedCrossRef

75.

Broer SL, Dólleman M, Opmeer BC, Fauser BC, Mol BW, Broekmans FJM. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum Reprod Update. 2011;17(1):46–54.PubMedCrossRef

76.

Poseidon G, Alviggi C, Andersen CY, Buehler K, Conforti A, De Placido G, et al. A new more detailed stratification of low responders to ovarian stimulation: from a poor ovarian response to a low prognosis concept. Fertil Steril. 2016;105(6):1452–3.CrossRef

77.

Nyboe Andersen A, Nelson SM, Fauser BCJM, García-Velasco JA, Klein BM, Arce J-C, et al. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril. 2017;107(2):387-96.e4.PubMedCrossRef

78.

Victoria M, Labrosse J, Krief F, Cédrin-Durnerin I, Comtet M, Grynberg M. Anti Müllerian hormone: more than a biomarker of female reproductive function. J Gynecol Obstet Hum Reprod. 2019;48(1):19–24.PubMedCrossRef

79.

Taylan E, Oktay KH. Current state and controversies in fertility preservation in women with breast cancer. World J Clin Oncol. 2017;8(3):241–8.PubMedPubMedCentralCrossRef

80.

Sanchez-Serrano M, Novella-Maestre E, Rosello-Sastre E, Camarasa N, Teruel J, Pellicer A. Malignant cells are not found in ovarian cortex from breast cancer patients undergoing ovarian cortex cryopreservation. Hum Reprod. 2009;24(9):2238–43.PubMedCrossRef

81.

Forman EJ. Ovarian tissue cryopreservation: still experimental? Fertil Steril. 2018;109(3):443–4.PubMedCrossRef

82.

Sermondade N, Sonigo C, Sifer C, Valtat S, Ziol M, Eustache F, et al. Serum antimullerian hormone is associated with the number of oocytes matured in vitro and with primordial follicle density in candidates for fertility preservation. Fertil Steril. 2019;111(2):357–62.PubMedCrossRef

83.

Blumenfeld Z, Haim N. Prevention of gonadal damage during cytotoxic therapy. Ann Med. 1997;29(3):199–206.PubMedCrossRef

84.

Oktay K, Bedoschi G. Appraising the biological evidence for and against the utility of GnRHa for preservation of fertility in patients with cancer. J Clin Oncol. 2016;34(22):2563–5.PubMedCrossRef

85.

Abdel-Razeq H. Gonadotropin-releasing hormone agonists during chemotherapy for ovarian function and fertility preservation for patients with early-stage breast cancer. Cancer Manag Res. 2019;11:4273–82.PubMedPubMedCentralCrossRef

86.

Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(19):1994–2001.PubMedCrossRef

87.

Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. Tailoring therapies–improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26(8):1533–46.PubMedPubMedCentralCrossRef

88.

Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015;372(10):923–32.PubMedPubMedCentralCrossRef

89.

Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA. 2011;306(3):269–76.PubMed

90.

Paluch-Shimon S, Pagani O, Partridge AH, Bar-Meir E, Fallowfield L, Fenlon D, et al. Second international consensus guidelines for breast cancer in young women (BCY2). Breast. 2016;26:87–99.PubMedCrossRef

91.

Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist. 2007;12(9):1044–54.PubMedCrossRef

92.

Zhong Y, Lin Y, Cheng X, Huang X, Zhou Y, Mao F, et al. GnRHa for ovarian protection and the association between AMH and ovarian function during adjuvant chemotherapy for breast cancer. J Cancer. 2019;10(18):4278–85.PubMedPubMedCentralCrossRef

93.

Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500–10.PubMedPubMedCentralCrossRef

94.

Umer S, Zhao SJ, Sammad A, WeldegebriallSahlu B, Yunwei P, Zhu H. AMH: Could it be used as a biomarker for fertility and superovulation in domestic animals? Genes. 2019;10(12):1009.CrossRefPubMedCentral

95.

Roness H, Spector I, Leichtmann-Bardoogo Y, Savino AM, Dereh-Haim S, Meirow D. Pharmacological administration of recombinant human AMH rescues ovarian reserve and preserves fertility in a mouse model of chemotherapy, without interfering with anti-tumoural effects. J Assist Reprod Genet. 2019;36(9):1793–803.PubMedPubMedCentralCrossRef

96.

Segev DL, Hoshiya Y, Stephen AE, Hoshiya M, Tran TT, MacLaughlin DT, et al. Mullerian inhibiting substance regulates NFkappaB signaling and growth of mammary epithelial cells in vivo. J Biol Chem. 2001;276(29):26799–806.PubMedCrossRef

97.

Kushnir VA, Seifer DB, Barad DH, Sen A, Gleicher N. Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine. J Assist Reprod Genet. 2017;34(9):1105–13.PubMedPubMedCentralCrossRef

Title: A review on the relationship between anti-mullerian hormone and fertility in treating young breast cancer patients
Authors: Yixuan Song
Hong Liu
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Fertility
Breast Cancer
Breast Cancer
Amenorrhoea
Cytostatic Therapy
Published in: BMC Women's Health / Issue 1/2021
Electronic ISSN: 1472-6874
DOI: https://doi.org/10.1186/s12905-021-01420-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A review on the relationship between anti-mullerian hormone and fertility in treating young breast cancer patients

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Inflammatory vaginitis in women on long-term rituximab treatment for autoimmune disorders

Suicide and deliberate self-harm among women in Nepal: a scoping review

An exploratory analysis of work engagement among women with and without disordered eating

Pelvic congestion syndrome (PCS) as a pathology of postmenopausal women: a case report with literature review

Implementation of HPV-based screening in Burkina Faso: lessons learned from the PARACAO hybrid-effectiveness study

Does laparoscopic hysterectomy + bilateral salpingectomy decrease the ovarian reserve more than total abdominal hysterectomy? A cohort study, measuring anti-Müllerian hormone before and after surgery